

Index

a

- abatacept 171, 172
 Abbreviated New Drug Application (ANDA) 294
 absorption enhancers 343
 absorption, distribution, metabolism, excretion, and toxicity (ADMET) of drugs 130
 N-acetyl cysteine 611
 acid-degradable hydrogel-based particles (ADHPs) 398, 399
 actinorhodin 26
 active pharmaceutical ingredients (APIs) 224, 225
 activity-based probe profiling (ABPP) 473, 474
 activity-based probes (ABPs) 472
 adalimumab 322
 adjuvants for recombinant vaccines 441, 442
 adsorption chromatography 188
 affinity-based probes (AFBPs) 472
 affinity chromatography 188
Agrobacterium tumefaciens 61
 AIDS vaccine 375–378
 alefacept 172
 allele-specific inhibition (ASI) 576
 alternative therapies 605, 606
 Alzheimer's disease (AD) 488
 amino acids, essential 610, 611
 amorpho-4,11-diene 20
 amorphadiene synthase 21
 amphiphilic block-graft copolymers 405–407
 amphotericin
 – microorganism production 16
Anthriscus sylvestris 508, 509
 antibody dependent cellular cytotoxicity (ADCC) 228, 229, 323
 anticancer drug discovery 477, 478
 anti-citrullinated peptide antibodies (aCPAs) 137
 antidiabetic drug discovery 477
 anti-drug-antibodies (ADAs) 224, 245, 352
 antifungal drug discovery 477
 antigen presenting cells (APCs) 392–394, 430
 antigen targeting 437
 – humoral immune response 437, 438
 antimicrobial drug resistance 477
 antiviral assay (AVA) 228, 329
 applicability domain 121
 aqueous two-phase extraction (ATPE) systems 186
Arabidopsis 510, 511
 arachidonic acid (ARA) 609, 610
 aranciamycin
 – biosynthetic gene expression production 18
 – microorganism production 16
 – structure 17
 archaeosomes 402, 403
 L-arginine 611
 arnica Montana 616
Artemisia annua 511, 512
 artemisinic acid 20, 514
 artemisinin 494, 511, 512
 artificial lymph node (ALN) 127, 128
 artificial proteins 171, 172
 assays, *in vitro* 129, 130
 atmospheric pressure chemical ionization (APCI) 212
 attenuated bacterial vaccines, recombinant 433
 aureothin
 – microorganism production 16
 automated rule induction systems (ARIS) 121

- avilamycin
 - microorganism production 16
 - structure 17
- b**
- Bacillus* species
 - *B. subtilis* 22
 - recombinant therapeutic proteins 30, 31
- bacterial–fungal interactions 19
- basiliximab 321
- batch cell microarrays 469
- batch chromatography 196, 197
- bead array technology 234
- Beer–Lambert Law 201
- beta-amyloid senile plaques (SPs) 488
- bicistronic tetracycline-responsive expression cassette (NTA) 81
- binding assays 222–224
- bioactivity
 - antibody dependent cellular cytotoxicity (ADCC) 228, 229
 - antiviral assay (AVA) 228
 - assay qualification and validation 230, 231
 - bead array technology 234
 - binding assays 222–224
 - bioassays 219–221
 - cell-based assays (CBA) 225, 226
 - complement dependent cytotoxicity (CDC) 229
 - cytotoxicity assay 227, 228
 - definition 221, 222
 - enzyme linked immuno-spot (ELISPOT) assays 230
 - Fc γ -receptor binding assays (Fc γ -RA) 222, 223
 - flow-cytometric assays (FACS) 230
 - immunogenicity testing 234, 235
 - ligand binding assay (LBA) 222
 - neutralizing assay 227
 - proliferation assay 226
 - reporter gene assays 229, 230
 - surface plasmon resonance spectroscopy (SPR-spectroscopy) 223, 224
- biobetter 64
- biobricks 9
- biochips for personalized medicine 566, 567
- biodegradable nanoparticles
 - acid-degradable hydrogel-based particles (ADHPs) 398, 399
 - poly(*D,L*-lactic-co-glycolic acid) (PLGA) and polylactic acid (PLA) 396–398
- bioinformatics 140, 141, 560
- biological therapies 574
 - cell therapy 575, 576
 - gene therapy 576
 - monoclonal antibodies 575
 - recombinant human proteins 575
 - RNA interference 576, 577
- Biologics License Application (BLA) 265, 295
- biomarkers 136–138
 - personalized medicine 559, 560
- Biomolecular Interaction Network Database (BIND) 134
- bioreactors, dynamic 127, 128
- Biosimilar Act 296
- biosimilars 3, 174–176, 285, 286, 332, 333
 - analysis method development 328–330
 - definition 287–290
 - development and requirements 325, 326
 - first wave in EU 305, 306, 313
 - – erythropoietin (EPO) 307–310
 - – granulocyte-colony stimulating factor (G-CSF) 310–312
 - – human growth hormone (hGH) 306, 307
 - – interferons and insulin (rejected) 312, 313
 - non-clinical and clinical development 330, 331
 - patents 297–305
 - process development 327, 328
 - regulation 266, 267, 297
 - – basic principles 290, 291
 - – European guidelines 291–294
 - – other territories 296, 297
 - – USA 294–296
 - second wave in EU
 - – PEGylated protein drugs 313–316
 - – recombinant antibodies and Fc-fusion proteins 316–325
- bird egg-extracted biopharmaceuticals 78
- black cohosh 616
- blood-extracted biopharmaceuticals 77
- bone marrow-derived mesenchymal stem cells (BM-MSCs) 484
- bromelain 616
- butyrylcholinesterase 75, 76
- c**
- C-terminal sequencing 217, 218
- 8-cadinine hydroxylase 21
- (+)- δ -cadinine synthase 21, 513, 514
- (+)-camphor 21
- canakinumab 322

- cancer vaccines, personalized 577, 578
 - *see also* nanobiotechnological strategies for cancer vaccines
- capillary electrophoresis (CE)
 - recombinant protein analysis 209, 210
- capillary gel electrophoresis (CGE) 210
- capreomycin
 - biosynthetic gene expression production 18
- capture chromatography 189, 190
- cardarchaeol 403
- β -carotene 20
- Carthamus tinctorius* 65
- (–)-carvone 20
- cation-exchange chromatography (CEX) 207, 208
- cationic liposomes–DNA complexes (CLDC) 402
- cell culture systems
 - cell fractions 122, 123
 - cell monolayers 123, 124
 - challenge on a chip 129
 - co-cultures, organotype cultures, and reconstituted tissue constructs 124
 - dynamic bioreactors 127, 128
 - *in vitro* assays 129, 130
 - multi-organ systems 128, 129
 - soma specific *in vitro* systems 127
 - stem cells 125–127
 - suspension cultures 123, 124
 - tissue engineering 125
 - Vitrocellomics project 130
- cell microarrays 469
 - applications 470
 - formats 470
 - types 469
 - – batch or non-positional 469
 - – positional 469
- cell therapy 575, 576
- cell-based assays (CBAs) 219–221, 225, 226
- cell-based proliferation assays (CSF) 329
- cellomics 132
- Center for Biologics Evaluation and Research (CBER) 262–265
- Center for Devices and Radiological Health (CDRH) 265
- Center for Drug Evaluation and Research (CDER) 262–265
- centrifugation 181, 182
- cephamycin C
 - biosynthetic gene expression production 18
- cetuximab 321
- challenge on a chip 129
- chaperone systems 27
- chemical ionization (CI) 212
- chemical microarrays 467
 - dry chemical microarray 468
 - immobilized technology 467
 - small molecule microarray (AMM) 467, 468
 - solution phase microarray 468, 469
- chemical proteomics 471
 - applications 475
 - probe structure 471, 472
 - strategies for drug discovery 473
 - – activity-based probe profiling 473, 474
 - – fragment-based probe profiling 474
- chemistry, manufacturing, and controls (CMC) 292, 293, 325
- chikungunya 443
- Chinese hamster ovary (CHO) cells 43
 - high-throughput bioprocess development 50, 51
 - process concepts 44–46
 - production cell lines 46, 47
 - rapid generation of high-producing cell lines 47, 48
 - stability of expression 49, 50
- chlorobiocin
 - biosynthetic gene expression production 18
- chondroitin 615
- chromatography 187
 - adsorption chromatography 188
 - affinity chromatography 188
 - batch chromatography 196, 197
 - capture chromatography 189, 190
 - column chromatography 187, 188
 - gas chromatography–mass spectrometry (GC-MS) 534
 - hydrophilic interaction chromatography (HILIC) 207
 - hydrophobic interaction chromatography (HIC) 189, 192, 193
 - hydroxyapatite (HA) chromatography 192
 - immobilized metal ion affinity chromatography (IMAC) 190
 - ion-exchange chromatography 191, 192, 207, 208
 - liquid chromatography–mass spectrometry (LC-MS) 534, 535
 - membrane chromatography 188, 189
 - micellar electrokinetic chromatography (MEKC) 210
 - polishing chromatography 191–193
 - reversed-phase chromatography (RPC) 193, 206, 207

- simulated moving bed chromatography (SMBC) 193, 194
 - size-exclusion chromatography (SEC) 193, 205, 206
 - ultrahigh pressure liquid chromatography–mass spectrometry (UPLC-MS) 535
 - circumsporozoite (CS) 439
 - cisplatin 463
 - clarification of liquids
 - centrifugation 181, 182
 - filtration 182–185
 - increasing efficiency 185, 186
 - cleaning and/or steaming in place (CIP/SIP) 189
 - click chemistry 474
 - clinical imaging 138–140
 - co-cultures 124
 - Cohn process 186
 - column chromatography 187, 188
 - Committee for Medicinal Products for Human Use (CHMP) 287
 - comparative genomic hybridization (CGH) 567
 - complement dependent cytotoxicity (CDC) 229, 323
 - complementary determining regions (CDR) 322
 - complex cell systems 485, 486
 - complex chromosomal rearrangements (CCRs) 556
 - computational pharmacology 457
 - computational therapeutics 457
 - conjugate vaccines 429
 - conjugated linoleic acid (CLA) 610
 - copy number variation (CNV) 557, 558
 - cross-flow filtration 183, 184
 - crystallization 196
 - cucuminoids 515
 - α -cyano-4-hydroxy-cinnamic acid (CHCA) 213
 - cycloserine
 - biosynthetic gene expression production 18
 - cysteine 611
 - cytogenetics and personalized medicine 567, 568
 - cytomics 132, 568
 - cytopathic effect (CPE) 228
 - cytotoxic T lymphocytes (CTLs) 392–403
 - cytotoxicity assay 227, 228
- d**
- daclizumab 321
 - daptomycin
 - biosynthetic gene expression production 18
 - microorganism production 16
 - data visualization 460
 - Database of Interacting Proteins (DIP) 134
 - databases for systems biology 487
 - daunorubicin
 - microorganism production 16
 - structure 17
 - dead-end filtration 183, 184
 - dehydrophos
 - biosynthetic gene expression production 18
 - denosumab 322
 - 6-deoxyerythronolide B (6dEB) 19–20
 - descriptor-based QSAR methods 458
 - development of new technologies into biomedicines 146
 - drug discovery and development 113, 114
 - models 114–116
 - strategic tool use 141, 142
 - – patient involvement 144, 145
 - – strategies 142, 143
 - – systems biology 143, 144
 - – tool variety 142
 - tools available 116, 117
 - – bioinformatics 140, 141
 - – biomarkers 136–138
 - – clinical imaging 138–140
 - – high-content screening (HCS) 131
 - – high-throughput screening (HTS) 131
 - – *in vitro* systems 122–131
 - – modeling and simulation 134–138
 - – omics approaches 131–134
 - translation as two-way process 145, 146
 - dhfr* gene 46, 47
 - diafiltration 194, 195
 - dialectic of vaccines 426, 427
 - dietary estrogens 612
 - dietary fibers 606
 - differential scanning calorimetry (DSC) 240
 - dihydrofolate reductase (DHFR) 43
 - 2,5-dihydroxybenzoic acid (DHB) 213
 - dimethyl dioctadecyl ammonium bromide (DDAB) 401
 - diode array detection (DAD) 205, 206
 - 1,2-dioleoyl-3-dimethyl ammonium propane (DODAP) 402
 - 1,2-dioleoyl-3-trimethyl ammonium propane (DOTAP) 401
 - N,N*-dioleoyl-*N,N*-dimethyl ammonium chloride (DODAC) 401

- diphtheria, tetanus, and pertussis (whooping cough) vaccine (DTaP) 428
- dipoyl-7-aminodesacetoxycephalosporanic acid 11
- Discrete Multiple Organ Culture (IdMOC®) system 128
- disposable bioreactors 51, 52
- DNA microarrays 463
- application to drug discovery 465, 466
 - – anticancer drugs 466
 - – bacterial disease diagnosis and therapy 466
 - – drug toxicity prediction 466
 - fabrication 464, 465
- DNA vaccines 429
- docosahexaenoic acid (DHA) 602
- docosahexanoic acid (DHA) 609, 610
- Donnan effect 243, 244
- dose–concentration–effect relationship 338
- downstream processing (DSP) 179, 180
- chromatography 187
 - – capture chromatography 189, 190
 - – column chromatography 187, 188
 - – membrane chromatography 188, 189
 - – polishing chromatography 191–193
 - clarification 181
 - – centrifugation 181, 182
 - – filtration 182–185
 - – increasing efficiency 185, 186
 - crystallization 196
 - filtration, fine 194
 - – ultrafiltration/diafiltration 194, 195
 - – virus filtration 195, 196
 - general principles 180, 181
 - recent developments 196, 197
- downstreaming fill and finish 242, 243
- doxorubicin
- structure 17
- drug approval 257
- EU regulation
 - – EMA 259, 260
 - – framework 257, 258
 - – new drug approval routes 260–262
 - international regulatory harmonization 265, 266
 - regulation of biosimilars 266, 267
 - US regulation 262
 - – approvals procedure 263–265
 - – CDER and CBER 263
- drug reactions (ADRs) 567
- drug-induced liver injury (DILI) 145, 146, 147
- drug-neutralizing antibodies (NABs) 224, 225, 227
- dry chemical microarray 468
- dynamic binding capacity (DBC) 187, 188
- dynamic bioreactors 127, 128
- dynamic light scattering (DLS) 241
- dysbiosis 611
- e**
- echinacea 615
- ecome 132
- eculizumab 321, 322
- eggs *see* bird eggs
- eicosapentaenoic acid (EPA) 610
- electron impact (EI) 212
- electrospray ionization (ESI) 212
- embryonic germ cells (EGCs) 91, 92
- embryonic stem cells 90, 91
- emulsions, sub-micron 404, 405
- encephalomyocarditis virus (EMCV) 228
- Engrailed-2 (EN2) 137
- enucleation 94, 95
- enzyme linked immuno-spot (ELISPOT) assays 230
- enzyme-linked immunosorbent assay (ELISA) 219, 222
- ephedra 615
- epigenomics 132
- epitholone 19, 20
- Erwinia uredovora* 20
- erythromycin
- microorganism production 16
 - – *E. coli* 19, 20
- erythropoietin (EPO) 307–310
- products 3
- Escherichia coli*
- host for natural product synthesis 19
 - – isoprenoids 20, 21
 - – polyketides 19, 20
 - – recombinant therapeutic proteins 27–30
- essential amino acids 610, 611
- ethical considerations
- patents 274, 281
 - – access to technology 277–280
 - – benefit sharing 280, 281
 - – no patents on nature 275, 276
 - – threats to human dignity 276, 277
- EU
- biosimilars 313
 - – erythropoietin (EPO) 307–310
 - – granulocyte-colony stimulating factor (G-CSF) 310–312
 - – guidelines 291–294, 305, 306
 - – human growth hormone (hGH) 306, 307

- interferons and insulin (rejected) 312, 313
 - PEGylated protein drugs 313–316
 - recombinant antibodies and Fc-fusion proteins 316–325
 - drug regulation
 - EMA 259, 260
 - framework 257, 258
 - new drug approval routes 260–262
 - European Federation of Pharmaceutical Industries and Associations (EFPIA) 115
 - European Product Assessment Reports (EPAR) 305
 - existing knowledge 117, 118
 - expression quantitative trait loci (eQTL) 147
 - expression vectors
 - recombinant therapeutic proteins 31
 - mRNA stability 33
 - promoter choice 32, 33
 - replication rate 31, 32
 - tag fusion 33
 - translation initiation 33, 34
- f**
- Familial Cold Auto-inflammatory Syndrome (FCAS) 5
 - fast atom bombardment (FAB) 212
 - fatty acids 609, 610
 - Fc-fusion proteins 316–325
 - Fc γ -receptors
 - binding assays (Fc γ -RA) 222, 223
 - neonatal
 - role in protein disposition 350, 351
 - federicamycin
 - biosynthetic gene expression production 18
 - field desorption/field ionization (FD/FI) 212
 - fill 242, 243
 - filtration 182–185
 - fine 194
 - ultrafiltration/diafiltration 194, 195
 - virus filtration 195, 196
 - finish 242, 243
 - flavonoids 515, 516, 607, 608
 - flow-cytometric assays (FACS) 226, 230
 - fluorescence activated cell sorting (FACS) 48
 - fluorescence *in situ* hybridization (FISH) 567
 - fluorescence spectroscopy
 - recombinant protein analysis 202, 203
 - follow-on biologics (FOBs) 294
 - food additives 604
 - food (dietary) supplements 604
 - Food and Drug Administration (FDA) 262
 - foot-and-mouth disease (FMD) 378
 - formulation strategies 235
 - recombinant proteins 244, 245
 - analytics 240, 241
 - downstreaming fill and finish 242, 243
 - dry formulations 238
 - highly concentrated protein formulations 243, 244
 - market development 241, 242
 - new proteins and related formulation aspects 244
 - screening 239, 240
 - stability of protein solutions 235–237
 - vaccines 245–247
 - analytics 247, 248
 - Fourier transform infrared spectroscopy (FTIR)
 - recombinant protein analysis 203–205
 - Fourier transform ion cyclotron resonance (FTICR) analyzers 213
 - fowlpox (FP) virus 432
 - fragment-based probe profiling 474
 - freeze drying 238
 - functional foods *see* nutraceuticals
 - fusion proteins 5
 - fusogenic liposomes (FLs) 403
- g**
- garlic 616
 - Gaucher's disease 63, 64
 - gel electrophoresis
 - recombinant protein analysis 208, 209
 - gelatin nanoparticles 404
 - gene expression profile screens (GEPS) 466
 - gene of interest (GOI) 46, 47, 49
 - gene pharming 72
 - gene polymorphisms 480, 481
 - gene therapy 576
 - GeneGo 134
 - GeneQuest 134
 - genetic variations in human genome 554, 555
 - complex chromosomal rearrangements (CCRs) 556
 - copy number variation (CNV) 557, 558
 - insertions and deletions (INDELs) 556, 557
 - large-scale variations 557
 - sequencing 565
 - single nucleotide polymorphisms (SNPs) 555, 556

- structural variations 558, 559
- genetically modified (GM) organisms 603, 619, 620
- genistein 494, 510, 511
- genome shuffling 24, 25
- genome-wide association studies (GWAS) 146, 147, 565, 566
- germacrene D-4-ol synthase 21
- Giardia lamblia* guanine PRT (GPRT) 460
- Ginkgo biloba 615
- ginseng 615
- α -glucocerebrosidase 7
- β -glucocerebrosidase 7, 8
- glutamine 611
- glutamine synthetase (gs) gene 47
- glutathione S-transferase (GST) 33
- glycine 46
- glycolysation 7
- goldenseal 615
- golimumab 322
- Gossypium hirsutum* 513, 514
- gossypol 513, 514
- granulocyte colony-stimulating factor (G-CSF) 305, 306, 310–312
- granulocyte-macrophage colony stimulating factor (GM-CSF) 305, 306
- green fluorescent protein, GFP 229

h

- hairy root cultures 497
- half-maximum effective concentration (EC50) 221
- haplotypes 479
- heat shock protein (HSP) 407
- hematopoietic stem cells (HSCs) 484
- herbal medicinal products (HMPs) 527
- herbal nutraceuticals 604, 605, 613, 614
- hierarchical cluster analysis (HCA) 536, 537
- high fidelity fallacy 116
- high throughput formulation screening (HTFS) 239–241
- high-content screening (HCS) 131
- high-throughput screening (HTS) 131, 453, 454, 488, 489
 - *see also* microarray HTS technology; RNA interference (RNAi) screening
 - quality, quantity and cost-effectiveness 454, 455
 - stem cells 483
 - – advantages 484
 - – applications 484, 485
 - – definition of stem cells 483, 484
 - – traditional versus novel targets 455, 456

- Hofmeister series 186
- host cell proteins (HCPs) 180, 327, 329
- HTS 239, 240
- human anti-mouse immunoglobulin antibody (HAMA) response 352
- Human Brain Proteomics Project (HBPP) 134
- human decay accelerating factor (hDAF) 582
- human dignity, threats to 276, 277
- human embryonic stem cells (hESCs) 126
- human genome project (HGP) 471, 477, 478
- human glucocerebrosidase
 - plant origin 63, 64
- human growth hormone (hGH) 296, 306, 307
- human insulin
 - prokaryotic cell production 36
- human papilloma virus (HPV) 410, 433
- human somatotropin (STH) 34, 35
- hydrodynamic radius 209
- hydrophilic interaction chromatography (HILIC)
 - recombinant protein analysis 207
- hydrophobic interaction chromatography (HIC) 189, 192, 193
- hydroxyapatite (HA) chromatography 192
- 5-*exo*-hydroxycamphor 21
- hypoxanthine 46

i

- imaging, clinical 138–140
- imiglucerase 7, 8
- immobilized metal ion affinity chromatography (IMAC) 190
- immune cell binding ligands (ICBL) 430
- immunogenicity
 - protein pharmacokinetics 352, 353
 - testing 234, 235
- immunopotentiating reconstituted influenza virosomes (IRIVs) 410, 411
- in chemico* approach 118, 119
- in silico* pharmacology 456, 457
 - applications 461
 - data visualization 460
 - quantitative structure–activity relationship (QSAR) 458
 - – descriptor-based methods 458
 - – knowledge-based methods 458
 - – rule-based methods 458
 - virtual affinity profiling 459
 - – ligand-based methods 459, 460
 - – target-based methods 460

- virtual ligand screening 457, 459
 - – ligand-based methods 459
 - – target-based methods 459
 - in silico* techniques
 - drug discovery 120, 121
 - methods 119, 120
 - modeling and simulation 485
 - toxicology 121, 122
 - in silico* toxicology 121, 122
 - in vitro* assays 129, 130
 - in vitro* systems 122
 - assays 129, 130
 - cell fractions 122, 123
 - cell monolayer or suspension cultures 123, 124
 - challenge on a chip 129
 - co-cultures, organotype cultures, and reconstituted tissue constructs 124
 - dynamic bioreactors 127, 128
 - multi-organ systems 128, 129
 - soma specific systems 127
 - stem cells 125–127
 - tissue engineering 125
 - Vitrocellomics project 130
 - independent component analysis (ICA) 536, 537
 - induced pluripotent stem cells (iPSCs) 92, 93, 126, 127, 484
 - infectomics 477
 - infliximab 321
 - influenza virus (H1N1) 65
 - informatics 140
 - informed consent 382
 - Ingenuity Pathway Analysis (IPA) 134
 - inhalation administration of proteins 341, 342
 - Innovative Medicines Initiative (IMI) 115
 - in-process controls (IPC) 328
 - insertions and deletions (INDELS) 556, 557
 - insulin 3
 - prokaryotic cell production 36
 - rejected biosimilar 312, 313
 - safflower production 64, 65
 - insulin lispro 6
 - integration deficient lentiviral vectors (IDLV) 432, 433
 - integrative genomics 476
 - applications 476, 477
 - – anticancer drug discovery 477, 478
 - – antidiabetic drug discovery 477
 - – antifungal drug discovery 477
 - – infectomics and antimicrobial drug resistance 477
 - – toxicogenomics for hepatotoxicity 478
 - integrative virtual screening 461
 - applications 463
 - – cisplatin tumor therapy 463
 - ligand-based methods 462
 - target-based methods 462
 - intellectual property (IP) protection 297, 298
 - interactomics 132
 - interferon
 - rejected biosimilar 312, 313
 - interferon-stimulated response elements (ISRE) 229, 230
 - International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) 265, 266
 - international non-proprietary name (INN) 290, 309
 - intranasal administration of proteins 342
 - inverted terminal repeats (ITRs) 89
 - ion cyclotron resonance (ICR) analyzers 213
 - ion trap (IT) analyzers
 - ion-exchange chromatography 191, 192
 - recombinant protein analysis 207, 208
 - iontophoresis 342
 - iron oxide nanoparticles 407, 408
 - isoflavon syntase (IFS) 510, 511
 - isoleucine 611
 - iso-migrastatin
 - biosynthetic gene expression production 18
 - isoprenoids
 - *E. coli* production 20, 21
- k**
- kaempferol 10
 - kava 616
 - knowledge-based QSAR methods 458
 - knowledge-based systems (KBS) 121
- l**
- lab-on-a-chip (LOC) 129
 - α -lactalbumin 73
 - β -lactoglobulin (BLG) 73, 74
 - landomycin A
 - biosynthetic gene expression production 18
 - microorganism production 16
 - Lavandula laetifolia* 511
 - lentiviruses 87, 88
 - leucine 611
 - leuprorelin 340
 - ligand binding assay (LBA) 222

- ligand epitope antigen presentation system (LEAPS) 430
 - (-)-limonene 20
 - limonene synthase 21
 - α -linolenic acid (ALA) 610
 - lipids 609, 610
 - lipomic profiling 475, 476
 - applications 476
 - - rosiglitazone in diabetes mellitus treatment 476
 - liposomal nanovectors 399, 400
 - archaeosomes 402, 403
 - fusogenic liposomes (FLs) 403
 - long-circulating liposomes 400, 401
 - positively charged liposomes 401, 402
 - liraglutid 7
 - log reduction values (LRVs) 180, 195
 - long terminal repeats (LTRs) 86
 - long-circulating liposomes (LCLs) 401
 - loss of heterozygosity (LOH) 576, 577
 - luteinizing hormone releasing hormone (LHRH) 340
 - lycopene 20, 23
 - lysine 611
 - m**
 - major histocompatibility complex (MHC) 392
 - maltose-binding protein (MBP) 33
 - mammalian cell production 43, 53, 54
 - CHO-derived production cell lines 46, 47
 - disposable bioreactors 51, 52
 - high-throughput bioprocess development 50, 51
 - process concepts 44-46
 - rapid generation of high-producing cell lines 47, 48
 - stability of expression 49, 50
 - transient gene expression (TGE) 52, 53
 - Market Authorization Application (MAA) 291
 - Marketing Authorization Applications (MAAs) 260, 261
 - mass spectrometry (MS)
 - medicinal plants 532, 533
 - - data processing 535, 537
 - - direct injection 533
 - - gas chromatography-mass spectrometry (GC-MS) 534
 - - liquid chromatography-mass spectrometry (LC-MS) 534, 535
 - recombinant protein analysis 211
 - - detectors 215
 - - disulfide linkage analysis 218, 219
 - - ionizer types and sources 212, 213
 - - mass analyzers 213-215
 - - N- and C-terminal sequencing by MALDI-ISD 217, 218
 - - operating principle 211
 - - peptide mass fingerprinting (PMF) 215-217
 - - sample introduction modes 211, 212
 - mass-to-charge ratio (m/z) 211
 - master cell bank (MCB) 327, 380
 - matairesinol 607
 - matrix assisted laser desorption ionization (MALDI) 212, 213, 214
 - MALDI In-Source Decay (MALDI-ISD)
 - - N- and C-terminal sequencing 217, 218
 - medical foods 603, 619, 620
 - medicinal plants 527, 528, 546, 547
 - bioanalytical tools 528-530
 - - data processing 535-537
 - - mass spectrometry (MS) 532, 533
 - - mass spectrometry (MS), direct injection 533
 - - mass spectrometry (MS), GC-MS 534
 - - mass spectrometry (MS), LC-MS 534, 535
 - - nuclear magnetic resonance (NMR) 531, 532
 - - sample preparation 530, 531
 - metabolic engineering
 - - artemisinin 511, 512
 - - genistein 510, 511
 - - gossypol 513, 514
 - - morphine 512, 513
 - - podophyllotoxin 508, 509
 - - scopolamine 509, 510
 - - spearmint limone synthase 511
 - metabolomics applications 538
 - - discrimination for classification 538-540
 - - identification of bioactivity 543, 544
 - - metabolite characterization 540, 541
 - - plant toxicity 545, 546
 - - quality control 541-543
 - - study efficacy 544, 545
- medium-chain fatty acids (MCFAs) 610
- medium-chain triglycerides (MCTs) 610
- membrane chromatography 188, 189
- mesenchymal stem cells (MSCs) 484, 576
- metabolic engineering 491-495
 - challenges
 - - cell compartmentalization and tissue differentiation 507, 508
 - - species specific pathways 507

- unexplored regulation of secondary metabolism 506, 507
- unpredicted or unexpected outcome 508
- future prospects 516, 517
- medicinal plant biotechnology
 - artemisinin 511, 512
 - genistein 510, 511
 - gossypol 513, 514
 - morphine 512, 513
 - podophyllotoxin 508, 509
 - scopolamine 509, 510
 - spearmint limone synthase 511
- microorganism production of heterologous plant compounds
 - artemisinic acid 514
 - cucuminoids 515
 - flavonoids 515, 516
 - stilbenes 514, 515
 - vanillin 516
- optimizing biochemical pathways
 - metabolic pathways of interest 499–501
 - strategies and goals 498, 499
 - synthetic biology 501, 502
- plants as sources of natural products
 - cell cultures 495, 496
 - transgenic plants 496–498
- strategies and techniques in medical plant biotechnology 502, 503
- downregulating of pathways 506
- redirecting common precursors 505
- storage of overproduced metabolites 506
- targeting metabolites 505
- upregulating of pathways 504
- metabolomics 132, 546, 547
- applications 538
 - discrimination for classification 538–540
 - identification of bioactivity 543, 544
 - metabolite characterization 540, 541
 - plant toxicity 545, 546
 - quality control 541–543
 - study efficacy 544, 545
- Methanosarcina barkeri* 22
- methicillin-resistant *Staphylococcus aureus* (MRSA) 561
- methicillin-sensitive *S. aureus* (MSSA) 561
- methionine 611
- methionine sulfoximine (MSX) 47
- methotrexate (MTX) 47
- 6-methyl-salicylic acid (6-MSA) 19, 20
- micellar electrokinetic chromatography (MEKC) 210
- microarray HTS technology
 - *see also* high-throughput screening (HTS)
 - cell microarray 469
 - applications 470
 - formats 470
 - types 469, 470
 - chemical microarray 467
 - dry chemical microarray 468
 - immobilized technology 467
 - small molecule microarray (AMM) 467, 468
 - solution phase microarray 468, 469
 - DNA microarray 463
 - application to drug discovery 465, 466
 - fabrication 464, 465
- microarrays
 - personalized medicine 566, 567
- micro-electromechanical-systems (MEMS) 129
- microfiltration 183
- microinjection 83–85
- microorganisms, natural products from 15
 - cloning and biosynthetic gene expression 18, 19
 - *E. coli* as host 19–21
 - heterologous plant compound production
 - artemisinic acid 514
 - cucuminoids 515
 - flavonoids 515, 516
 - stilbenes 514, 515
 - vanillin 516
 - production libraries 16
 - silent gene cluster wake up, culture manipulation 19
 - silent gene cluster wake up, genomic approaches 19
- micro-organoids 129
- micro-total analysis systems (μ -TAS) 129
- milk thistle 615
- milk-extracted biopharmaceuticals 73–76
- minigenes 79
- mithramycin
 - microorganism production 16
 - structure 17
- modeling and simulation
 - nature of and need for 114–116
 - pharmacokinetics 134, 135
 - virtual patient populations 136
 - virtual tissue modeling 135, 136
- modified vaccinia Ankara virus (MVA) 409, 431
- molecular biology 3–5
 - future prospects 11, 12

- production hosts and upstream/downstream processing 10, 11
 - research developments
 - – muteins 6, 7
 - – post-translational engineering 7, 9
 - – protein engineering 5
 - – synthetic biology 9, 10
 - molecular diagnosis for personalized medicine 560, 561
 - point-of-care diagnostics 564
 - real-time PCR 561–563
 - single biomolecule analysis 563, 564
 - Molecular INTERaction database (MINT) 134
 - monoclonal antibodies 575
 - products 3
 - monophosphoryl lipid A (MPL) 441, 442
 - monoterpenes 608, 609
 - morphine 494, 512, 513
 - mouse embryonic stem cell (mESC) 126
 - mRNA stability 33
 - Muckle–Wells Syndrome (MWS) 5
 - Multi Compartmental Bioreactor (MCB) 129
 - multi-organ systems 128, 129
 - multiparametric metabolic responses 132
 - multivalent antigen presentation 439, 440
 - self-adjuvanting agents 441
 - self-assembling peptide nanoparticles 440
 - muteins 6, 7
- n**
- N-terminal sequencing 217, 218
 - nanobiotechnological personalized medicine 572, 573
 - cancer vaccines 577, 578
 - nanobiotechnological strategies for cancer vaccines 391–395, 412
 - amphiphilic block-graft copolymers 405–407
 - biodegradable nanoparticles
 - – acid-degradable hydrogel-based particles (ADHPs) 398, 399
 - – poly(*D,L*-lactic-co-glycolic acid) (PLGA) and polylactic acid (PLA) 396–398
 - gelatin nanoparticles 404
 - iron oxide nanoparticles 407, 408
 - – virosomes 410–412
 - – viruses 408–410
 - – virus-like particles (VLPs) 410
 - liposomal nanovectors 399, 400
 - – archaeosomes 402, 403
 - – fusogenic liposomes (FLs) 403
 - – long-circulating liposomes 400, 401
 - – positively charged liposomes 401, 402
 - nanocarrier cancer vaccines (NCVs) 391–395
 - personalized vaccines 577, 578
 - sub-micron emulsions 404, 405
 - nanofiltration 183
 - napyradiomycin
 - biosynthetic gene expression production 18
 - natural products from microorganisms 15
 - cloning and biosynthetic gene expression 18, 19
 - *E. coli* as host 19–21
 - production libraries 16
 - silent gene cluster wake up, culture manipulation 19
 - silent gene cluster wake up, genomic approaches 19
 - nefazodone 122
 - neurofibrillary tangles (NFTs) 488
 - neutralizing assay 227
 - new biological entities (NBEs) 5
 - New Drug Application (NDA) 295
 - new drug entities (NDEs) 3
 - Nicotiana tabacum* 509, 510
 - nikkomycin
 - biosynthetic gene expression production 18
 - nominal molecular weight cut-off (NMWCO) 194, 195
 - non-positional cell microarrays 469
 - non-small cell lung cancer (NSCLC) 400
 - novel foods 603
 - novobiocin
 - biosynthetic gene expression production 18
 - microorganism production 16
 - structure 17
 - nuclear magnetic resonance (NMR)
 - medicinal plants 531, 532
 - nutraceuticals 599–600
 - absorption, metabolism and interaction with drugs 616–618
 - concepts 601, 602
 - – alternative therapies 605, 606
 - – food (dietary) supplements 604
 - – food additives 604
 - – functional foods 602
 - – herbal nutraceuticals 604, 605
 - – medical foods 603
 - – novel foods 603
 - – phytonutrients 604
 - definition 602

- epidemiological study and clinical trials 618, 619
 - future prospects 621, 622
 - health issues 614–616
 - herbal nutraceuticals 604, 605, 613, 614
 - human health 600, 601
 - medical foods 619, 620
 - potential health benefits 606
 - – amino acids, essential 610, 611
 - – dietary fibers 606
 - – fatty acids and lipids 609, 610
 - – phenolic products 607, 608
 - – phytoestrogen 612, 613
 - – phytosterol 609
 - – prebiotics and probiotics 611, 612
 - – terpenoids 608, 609
 - nystatin
 - microorganism production 16
- o**
- ofatumumab 322
 - omics approaches 131, 485
 - application 132, 133
 - information handling 133, 134
 - personalized medicine 568
 - – pharmacogenetics 568, 569
 - – pharmacogenomics 569, 570
 - – pharmacometabolomics 570–572
 - – pharmacoproteomics 570
 - strain improvement 22
 - variety 132
 - one strain many compounds (OSMAC) theory 19
 - optical coherence topography (OCT) 139
 - Optimata Virtual Patients (OVPs) 136
 - oral administration
 - proteins 343
 - oral polio vaccine (OPV) 423
 - orbitrap analyzers 213
 - organotype cultures 124
 - orthogonal partial least squares discriminant analysis (OPLSDA) 537
 - Oryza sativa* 62
 - out of specification (OAS) 155
 - over the counter (OTC) drugs 527
 - oxytetracycline
 - biosynthetic gene expression production 18
- p**
- paclitaxel 494
 - Paired-End Mapping 559
 - panitumumab 322
 - Papaver somniferum* 512–514
 - parenteral administration of proteins 340, 341
 - partial least squares discriminant analysis (PLSDA) 537
 - partial least squares (PLS) regression 537
 - Patent and Trademark Office (PTO) 271, 272
 - patents in pharmaceutical biotechnology industry 269, 281
 - biosimilars 297–305
 - ethical and policy issues 274
 - – access to technology 277–280
 - – benefit sharing 280, 281
 - – no patents on nature 275, 276
 - – threats to human dignity 276, 277
 - patent law
 - – definition of patent 269–271
 - – infringement of patent 273, 274
 - – international law 274
 - – obtaining a patent 271, 272
 - – subject matter 272, 273
 - – types of patent 273
 - pathogen-associated molecular patterns (PAMPs) 441
 - patients
 - involvement 144, 145
 - modeling virtual populations 136
 - PCT, real-time 561–563
 - pegvisomant 9
 - PEGylated protein drugs 8, 9, 313–316
 - peptibody 5
 - peptides
 - mass fingerprinting (PMF) 215–217
 - pharmacokinetics 339
 - peripheral blood mononuclear cells (PBMC) 229
 - personalized medicine 553
 - biological therapies 574
 - – cell therapy 575, 576
 - – gene therapy 576
 - – – monoclonal antibodies 575
 - – – recombinant human proteins 575
 - – – RNA interference 576, 577
 - – biomarkers 559, 560
 - – development technologies 560
 - – future prospects 578, 579
 - – genetic variations in human genome 554, 555
 - – – complex chromosomal rearrangements (CCRs) 556
 - – – copy number variation (CNV) 557, 558
 - – – insertions and deletions (INDELS) 556, 557
 - – – large-scale variations 557

- single nucleotide polymorphisms (SNPs) 555, 556
- structural variations 558, 559
- molecular diagnosis 560, 561
- point-of-care diagnostics 564
- real-time PCR 561, 563
- single biomolecule analysis 563, 564
- personalized vaccines 577
- cancer vaccines 577
- viral diseases 577
- role of biochips/microarrays 566, 567
- role of cytogenetics 567, 568
- role of nanobiotechnology 572, 573
- role of omics 568
- pharmacogenetics 568, 569
- pharmacogenomics 569, 570
- pharmacometabolomics 570–572
- pharmacoproteomics 570
- sequencing 564, 565
- human genome variation 565
- rare variants and disease-causing genes 565, 566
- systems biology 573, 574
- pharmacogenetics 131, 560
- personalized medicine 568, 569
- test 561
- pharmacogenomics 131, 132, 560
- personalized medicine 569, 570
- pharmacogenomic test 561
- pharmacokinetics 327–329, 361
- exposure-related correlations for protein therapeutics 353, 354
- cell life span models 356–360
- direct link PK/PD models 354, 355
- indirect link PK/PD models 355
- indirect response PK/PD models 355, 356
- immunogenicity and proteins 352, 353
- modeling and simulation 134, 135
- peptides and proteins 339
- physiologically based pharmacokinetics (PBPK) 134, 135
- protein absorption 339, 340
- inhalation administration 341, 342
- intranasal administration 342
- oral administration 343
- parenteral administration 340, 341
- transdermal administration 342
- protein binding 345, 346
- protein disposition, role of neonatal Fc-receptor 350, 351
- protein distribution 343, 345
- protein elimination 346
- gastrointestinal metabolism 347
- hepatic metabolism 349
- proteolysis 346, 347
- receptor-mediated metabolism 349, 350
- renal metabolism 347–349
- pharmacometabolomics 560
- personalized medicine 570–572
- pharmacoproteomics 560
- personalized medicine 570
- Phaseolus vulgaris* 62
- phenalinolactones
- biosynthetic gene expression production 18
- microorganism production 16
- phenolic products 607, 608
- phenomics 132
- phenylalanine 611
- phosphoribosyltransferases (PRTs) 460
- physiologically based pharmacodynamic (PBPD) modelling 135
- phytoestrogen 612, 613
- phytonutrients 604
- phytosterol 609
- PiggyBac transposon 50, 89
- pigs as sources of transplantable tissues and organs 582, 583
- (+)- α -pinene 21
- plant biopharmaceuticals 59, 60, 67, 68
- *see also* medicinal plants
- basic considerations 60–62
- cell cultures 495, 496
- challenges in plant metabolic engineering
- cell compartmentalization and tissue differentiation 507, 508
- species specific pathways 507
- unexplored regulation of secondary metabolism 506, 507
- unpredicted or unexpected outcome 508
- future prospects 516, 517
- human glucocerebrosidase 63, 64
- insulin from safflower 64, 65
- microorganism production of heterologous plant compounds
- artemisinic acid 514
- cucuminoids 515
- flavonoids 515, 516
- stilbenes 514, 515
- vanillin 516
- strategies and techniques in medical plant biotechnology 502, 503
- downregulating of pathways 506
- redirecting common precursors 505
- storage of overproduced metabolites 506

- targeting metabolites 505
- upregulating of pathways 504
- tobacco-based expression systems 65–67
- transgenic plants 496–498
- pluripotent cells
 - embryonic germ cells 91, 92
 - embryonic stem cells 90, 91
 - induced pluripotent stem cells (iPSCs) 92, 93, 126, 127, 484
- podophyllotoxin 494, 508, 509, 607
- point-of-care diagnostics for personalized medicine 564
- polishing chromatography 191–193
- poly(*D,L*-lactic-co-glycolic acid) (PLGA) 396–398
- polyethylene glycol (PEG) 8, 9
- polyketides
 - *E. coli* production 19, 20
- polylactic acid (PLA) 398
- polyunsaturated fatty acids (PUFAs) 600, 609, 610
- Pompe's disease 75
- porcine endogenous retrovirus (PERV) 591
- positional cell microarrays 469
- positron emission tomography (PET) 139, 563
- post-translational engineering 7, 9
- prebiotics and probiotics 611, 612
- prediction model (PM) 130
- prime–boost staging 438
 - case study 438, 439
 - targeting conserved/invariant region 439
- primordial germ cells (PGCs) 91
- principal component analysis (PCA) 536, 540
- process analytical technology (PAT) 197
- production hosts 10, 11
- production methods
 - mammalian cells 43, 53, 54
 - CHO-derived production cell lines 46, 47
 - disposable bioreactors 51, 52
 - high-throughput bioprocess development 50, 51
 - process concepts 44–46
 - rapid generation of high-producing cell lines 47, 48
 - stability of expression 49, 50
 - transient gene expression (TGE) 52, 53
 - plant biopharmaceuticals 59, 60, 67, 68
 - basic considerations 60–62
 - human glucocerebrosidase 63, 64
 - insulin from safflower 64, 65
 - tobacco-based expression systems 65–67
 - prokaryotic cells 15
 - natural products from microorganisms 15–26
 - recombinant therapeutic proteins 26–36
 - transgenic animal biopharmaceuticals 71–73, 104, 105
 - analysis of transgenic animals 99–102
 - constructs 78–82
 - production of transgenic animals 82–99
 - quality and safety of products 102–104
 - recombinant protein sources 73–78
- prokaryotic cell production 15
 - natural products from microorganisms 15
 - cloning and biosynthetic gene expression 18, 19
 - *E. coli* as host 19–21
 - production libraries 16
 - silent gene cluster wake up, culture manipulation 19
 - silent gene cluster wake up, genomic approaches 19
 - strain improvement strategies 21–26
 - recombinant therapeutic proteins 26, 27
 - expression vectors 31–34
 - host strains 27–31
 - production steps 34
 - products 34–36
 - prokaryotic expression systems 27–34
- proliferation assay 226
- pronuclear DNA microinjection 83
- N*-propionyl cysteaminyphenol 407
- prostate specific antigen (PSA) 137
- Protein A chromatography 190
- Protein Structural Interactome Map (PSIMAP) 134
- proteins
 - *see also* recombinant proteins
 - administration
 - inhalation administration 341, 342
 - intranasal administration 342
 - oral administration 343
 - parenteral administration 340, 341
 - transdermal administration 342
 - artificial 171, 172
 - binding 345, 346
 - disposition
 - role of neonatal Fc-receptor 350, 351

- distribution 343–345
 - elimination 346
 - – gastrointestinal metabolism 347
 - – hepatic metabolism 349
 - – proteolysis 346, 347
 - – receptor-mediated metabolism 349, 350
 - – renal metabolism 347–349
 - engineering 5
 - exposure-related correlations for protein therapeutics 353, 354
 - – cell life span models 356–360
 - – direct link PK/PD models 354, 355
 - – indirect link PK/PD models 355
 - – indirect response PK/PD models 355, 356
 - immunogenicity 352, 353
 - pharmacokinetics 339
 - proteomics 132
 - proton magnetic resonance spectroscopic imaging (PMRSI) 139
 - protoplast fusion 24, 25
 - Pure Red Cell Aplasia (PRCA) syndrome 309, 310, 328
 - puromycin
 - biosynthetic gene expression production 18
- q**
- quadrupole analyzers 213
 - quality by design (QbD) 197
 - quantitative structure–activity relationship (QSAR) 458
 - descriptor-based methods 458
 - knowledge-based methods 458
 - rule-based methods 458
 - quercetin 10
- r**
- rapamycin
 - microorganism production 16
 - ravidomycin
 - biosynthetic gene expression production 18
 - REACH (Registration, Evaluation, Authorization, and Restriction of Chemical Substances) system 141
 - real-time PCR 561, 563
 - recombinant antibodies 316–325
 - recombinant drugs 155–166
 - artificial proteins 171–172
 - biosimilars 174–176
 - classification 166
 - expression systems 167–170
 - proteins derived from recombinant genes 170, 171
 - – post-expression modification 173
 - recombinant human erythropoietin (rhEPO) 359, 360
 - recombinant human proteins 575
 - recombinant proteins 26, 27, 170, 171, 201, 286, 287
 - biological characterization *in vitro*
 - – antibody dependent cellular cytotoxicity (ADCC) 228, 229
 - – antiviral assay (AVA) 228
 - – assay qualification and validation 230, 231
 - – bead array technology 234
 - – binding assays 222–224
 - – bioactivity, defining 221, 222
 - – bioassays 219–221
 - – cell-based assays (CBA) 225, 226
 - – complement dependent cytotoxicity (CDC) 229
 - – cytotoxicity assay 227, 228
 - – enzyme linked immuno-spot (ELISPOT) assays 230
 - – Fcγ-receptor binding assays (Fcγ-RA) 222, 223
 - – flow-cytometric assays (FACS) 230
 - – immunogenicity testing 234, 235
 - – ligand binding assay (LBA) 222
 - – neutralizing assay 227
 - – outlook 231
 - – proliferation assay 226
 - – reporter gene assays 229, 230
 - – surface plasmon resonance spectroscopy (SPR-spectroscopy) 223, 224
 - classification 4
 - expression vectors 31
 - – mRNA stability 33
 - – promoter choice 32, 33
 - – replication rate 31, 32
 - – tag fusion 33
 - – translation initiation 33, 34
 - formulation strategies 244, 245
 - – analytics 240, 241
 - – downstreaming fill and finish 242, 243
 - – dry formulations 238
 - – formulation and stability of solutions 235–237
 - – formulation development for market 241, 242
 - – highly concentrated formulations 243, 244
 - – screening strategies 239, 240

- host strains
 - – *Bacillus* species 30, 31
 - – *E. coli* 27–30
 - – other species 31
 - physical chemical characterization
 - – capillary electrophoresis (CE) 209, 210
 - – fluorescence spectroscopy 202, 203
 - – Fourier transform infrared spectroscopy (FTIR) 203–205
 - – gel electrophoresis 208, 209
 - – hydrophilic interaction chromatography (HILIC) 207
 - – ion-exchange chromatography 207, 208
 - – mass spectrometry (MS) 211–219
 - – other methods 210
 - – reversed-phase chromatography (RPC) 206, 207
 - – size-exclusion chromatography (SEC) 205, 206
 - – ultraviolet absorption spectroscopy 201, 202
 - post-expression modification 173
 - production steps 34
 - products 34
 - – human insulin 36
 - – somatropin 34, 35
 - prokaryotic expression systems 27–34
 - top selling 4
 - transgenic animal sources
 - – bird eggs 78
 - – blood 77
 - – milk 73–76
 - – seminal fluid 77
 - – urine 76, 77
 - recombinant vaccines 423, 443, 444
 - *see also* vaccines
 - clinical trials 443
 - comparing efficiency 427
 - current market range 424–426
 - delivery systems 435, 436
 - development 433
 - – deliverability and accessibility 434, 435
 - – manufacturability 433, 434
 - – scalability 434
 - dialectic 426, 427
 - identifying attenuated vaccine strains
 - – biological–molecular combination 442, 443
 - overview 428
 - – attenuated bacterial vaccines, recombinant 433
 - – conjugate vaccines 429
 - – DNA vaccines 429
 - – subunit vaccines 428, 429
 - – T-cell receptor peptide and T-cell epitope conjugate vaccines 430
 - – viral vectors 431, 433
 - – virus-like particles (VLPs) 430, 431
 - vanguard technologies 436
 - – adjuvants 441, 442
 - – antigen targeting 437, 438
 - – multivalent antigen presentation 439–441
 - – prime–boost staging 438, 439
 - reconstituted tissue constructs 124
 - red cell aplasia (RCA) 225
 - regulator of complement activation (RCA) 81
 - reporter gene assays 229, 230
 - respiratory syncytial virus (RSV) vaccine 378
 - response units (RU) 223
 - reteplase 6
 - retrovirus vectors, recombinant 432, 433
 - retroviruses 88
 - reverse osmosis 183
 - reversed-phase chromatography (RPC) 193
 - recombinant protein analysis 206, 207
 - reversely transfected cell microarrays (RTCMs) 470
 - ribosome binding site (RBS) 33, 34
 - riloncept 5, 172
 - rituximab 3, 321
 - RNA interference (RNAi) screening 482, 576, 577
 - *see also* high-throughput screening (HTS)
 - applications for HTS 483
 - libraries for HTS 482, 483
 - romiplostim 5
 - rosiglitazone 476
 - rule-based QSAR methods 458
 - Rules Governing Medicinal Products in the European Union* 258
- S**
- Saccaropolyspora erythrea* 22
 - Saccharomyces cerevisiae* 22
 - Saccharomyces coelicolor* 22
 - Saccharopolyspora erythrea* 25
 - safflower
 - insulin production 64, 65
 - salinomycin 26
 - saquayamycin
 - microorganism production 16
 - saw palmetto 616
 - scaffold/matrix attachment regions (S/MARs) 49
 - scopolamine 494, 509, 510

- screening strategies 239, 240
 secoisolariciresinol 607
 self-advantaging agents 441
 self-assembled monolayer (SAM) 468
 self-assembling peptide nanoparticles for
 multivalent antigen presentation 440
 seminal fluid-extracted biopharmaceuticals
 77
 sequencing for personalized medicine 564,
 565
 – human genome variation 565
 – rare variants and disease-causing genes
 565, 566
 Shine–Dalgarno (SD) sequence 33, 34
 short tandem repeats (STRs) 464
 silencing 49, 50
 silent gene cluster wake up
 – culture manipulation 19
 – genomic approaches 19
 simulated moving bed chromatography
 (SMBC) 193, 194
 simulation *see* modeling and simulation
 sinapinic acid (SA) 213
 single biomolecule analysis for personalized
 medicine 563, 564
 single nucleotide polymorphisms (SNPs)
 464, 479, 480, 481, 555, 556
 sitagliptin 11
 size-exclusion chromatography (SEC) 193
 – recombinant protein analysis 205, 206
 small molecule microarray (AMM) 467,
 468
 sodium dodecyl sulfate–polyacrylamide gel
 electrophoresis (SDS–PAGE) 209
 solution phase microarray 468, 469
 soma specific *in vitro* systems 127
 somatic cell nuclear transfer (SCNT) 94–98
 somatropin
 – prokaryotic cell production 34, 35
 sonoporation 342, 436
 spacers 472
 spearmint limone synthase 511
 specific pathogen-free (SPF) 434
 sperm mediated gene transfer 88, 89
 spermatogonial stem cells 93, 94
 spinosyn
 – microorganism production 16
 St. John's wort 542, 616
 Standardized Operating Procedure (SOP)
 231
Staphylococcus aureus 20
 staurosporin
 – biosynthetic gene expression production
 18
 – microorganism production 16
 – structure 17
 stealth liposomes 401
 stem cells 125–127
 – definition 483, 484
 – high-throughput screening (HTS) 483
 – advantages 484
 – applications 484, 485
 stilbenes 514, 515
 Stoke's radius 194
 strain improvement strategies 21
 – synthetic biology tools 22, 23
 – promoter library 23
 – tunable intergenic regions library 23,
 24
 – system biology, system biotechnology and
 omic approaches 21, 22
 – translation and transcription engineering
 25, 26
 – whole genome engineering 24
 – protoplast fusion and genome shuffling
 24, 25
 streptomycin
 – biosynthetic gene expression production
 18
 structure–activity relationship (SAR) 458
 sub-micron emulsions 404, 405
 subunit vaccines 428, 429
 supplementary protection certificates (SPC)
 298
 surface plasmon resonance spectroscopy
 (SPR-spectroscopy) 223, 224, 468
 suspension cultures 123, 124
 synthetic biology 9, 10, 22, 23
 – promoter library 23
 – tunable intergenic regions library 23, 24
 system biotechnology 22
 systems biology 21, 22, 143, 144
 – drug discovery 485
 – applications 486–488
 – industry approaches 485, 486
 – simulation models 486
 – personalized medicine 573, 574
- t**
 T-cell epitope conjugate vaccines 430
 T-cell receptor peptide vaccines 430
 tag fusion 33
 tags 471, 472
 Tamm Horsfall protein 76
 taxadiene synthase 21
 terpenoids 608, 609
 thermospray ionization (TSP) 212
 thiazolylpeptide GE2270 26

- thiocoraline
 - biosynthetic gene expression production 18
 - thioredoxin (Trx) 33
 - thunder god vine 616
 - thymidine 46
 - time-of-flight (TOF) analyzers 213
 - time-resolved fluorescence resonance energy transfer (TR-FRET) 455
 - tissue engineering 125
 - tissue plasminogen activators (tPAs) 6
 - tissues
 - virtual modeling 135, 136
 - tobacco mosaic virus (TMV) 62
 - tobacco-based expression systems 65–67
 - Toll-like receptors (TLR) 437, 441
 - ligands 394
 - N-tosyl-L-phenylalanine chloromethyl ketone (TPCK) 216
 - toxicogenomics 132, 478, 479
 - animal models 480
 - applications 481
 - drug discovery 479, 480
 - gene polymorphisms 480, 481
 - hepatotoxicity 478
 - *in vitro* models 480
 - toxoid vaccines 428
 - Trade Related Aspects of Intellectual Property agreement (TRIPS) 274
 - trans fats 610
 - transcription activator-like effector (TALE) nucleases 99
 - transcriptomics 132
 - transdermal administration
 - proteins 342
 - transgenic animal biopharmaceuticals 71–73, 104, 105
 - analysis of transgenic animals 99
 - – collection, processing, and protein purification 101, 102
 - – integrated transgenes 100, 101
 - – transgene expression profile 101
 - animal production methods 82
 - – DNA injection 83, 84
 - – DNA preparation 83
 - – fertilised egg collection 83
 - – founders identification and breeding 85, 86
 - – highly specific DNA endonucleases 99
 - – pluripotent stem cells 90–93
 - – pronuclear DNA microinjection 83
 - – somatic cell nuclear transfer 94–98
 - – sperm mediated gene transfer 88, 89
 - – spermatogonial stem cells 93, 94
 - – transfer and gestation 84, 85
 - – transposon mediated gene transfer 89
 - – viral mediated gene transfer 86–88
 - constructs 78–80
 - irreducible expression 81
 - non-integrating vectors 81, 82
 - organ specific expression vectors 80
 - quality and safety of products 102–104
 - recombinant protein sources 73
 - bird eggs 78
 - blood 77
 - milk 73–76
 - seminal fluid 77
 - urine 76, 77
 - transgenic plants 496–498
 - transient gene expression (TGE) systems 46, 52, 53
 - transposon mediated gene transfer 89
 - tryptophan 203, 611
 - TubeSpins 50, 51
 - tumor-associated antigens (TAAs) 392–394
 - tunable intergenic regions (TIGRs) 24
 - tylosin
 - microorganism production 16
 - tyrosine 611
- u**
- ubiquitous chromatin opening elements (UCOE) 49
 - ultrafiltration 183, 194, 195
 - ultrahigh pressure liquid chromatography–mass spectrometry (UPLC-MS) 535
 - ultrasound and microbubble targeted delivery (UMTD) 436
 - ultraviolet absorption spectroscopy
 - recombinant protein analysis 201, 202
 - upstream/downstream processing 10, 11
 - urine-extracted biopharmaceuticals 76, 77
 - uromodulin 76
 - uroplakins 76
 - USA
 - drug regulation 262
 - – approvals procedure 263–265
 - – biosimilars 294–296
 - – CDER and CBER 263
 - ustekinumab 322
- v**
- vaccina virus, recombinant 431, 432
 - vaccine associated paralytic poliomyelitis (VAPP) 423
 - vaccines 371, 387, 388, 391–395
 - *see also* recombinant vaccines
 - conventional

- toxoid 428
 - whole organism 428
 - economic aspects of development 384
 - costs of development 384–386
 - risks and opportunities 386, 387
 - formulation strategies 245–247
 - analytics 247, 248
 - from research concept to development
 - candidate 372, 373
 - overview 428
 - personalized 577
 - cancer vaccines 577, 578
 - viral diseases 577
 - recombinant DNA approach to identifying attenuated vaccine strains
 - biological–molecular combination 442, 443
 - research projects 373–375
 - scientific challenges of R&D 375–378
 - technical aspects of development 379, 380
 - clinical development 382, 383
 - licensing and registration 383, 384
 - manufacturing facilities 381, 382
 - preclinical development 380, 381
 - valerian 616
 - valine 611
 - vancomycin
 - microorganism production 16
 - structure 17
 - vanillin 494, 516
 - (+)-*cis*-verbenol 21
 - vesicular stomatitis virus (VSV) 228
 - vincristine 494
 - viral mediated gene transfer 86–88
 - viral vectors 431
 - fowlpox (FP) virus 432
 - retrovirus vectors, recombinant 432, 433
 - vaccinia virus, recombinant 431, 432
 - virosomes 410–412
 - virtual affinity profiling 459
 - ligand-based methods 459, 460
 - target-based methods 460
 - virtual ligand screening 457, 459
 - ligand-based methods 459
 - target-based methods 459
 - virtual patient populations 136
 - virtual tissue modeling 135, 136
 - Virtual ToxLab* 122
 - virus filtration 195, 196
 - virus-like particles (VLPs) 66, 410, 430, 431
 - viruses 408–410
 - visualization of data 460
 - Vitrocellomics project 130
- W**
- West Nile virus (WNV) 437, 444
 - whey acidic protein (WAP) 73, 80
 - whole organism vaccines 428
 - working cell bank (WCB) 327, 380
- X**
- xenotransplantation 581
 - alternative sources of transplantable tissues 581, 582
 - pigs 582, 585
 - biological barriers
 - accommodation 588
 - acute vascular rejection 586–588
 - cellular mediated immune response 588, 589
 - complement activation 585, 586
 - graft vascularization 583, 584
 - hyperacute rejection 584, 585
 - clinical applications 592, 593
 - physiological and infectious barriers
 - interspecies challenges 590, 591
 - zoonosis 591
- Z**
- zeaxanthin 20
 - zinc-finger nucleases (ZFNs) 99
 - zoonosis 591

